N-(4-chloro-2-fluoro-phenyl)-5'-O-trifluoromethyl-adenosine | 1054654-94-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: N-(4-chloro-2-fluoro-phenyl)-5'-O-trifluoromethyl-adenosine
• 英文别名: (2R,3R,4S,5R)-2-[6-(4-chloro-2-fluoroanilino)purin-9-yl]-5-(trifluoromethoxymethyl)oxolane-3,4-diol
• CAS: 1054654-94-2
• 化学式: C₁₇H₁₄ClF₄N₅O₄
• 分子量: 463.776
• InChiKey: PHRPWMQHKYAEIP-XNIJJKJLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• Formulations of adenosine a1 agonists
  申请人：——

  公开号：US20030018008A1

  公开（公告）日：2003-01-23

  The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and a 5HT 3 antagonist or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

  本发明提供了一种治疗与疼痛相关的症状并缓解相关症状的方法，包括向哺乳动物，包括人类，施用腺苷A1受体激动剂或其生理上可接受的盐或溶剂以及5HT3拮抗剂或其生理上可接受的盐或溶剂。本发明还提供了包含这些组合物的药物配方和患者包。
• Formulations of adenosine A1 agonists
  申请人：——

  公开号：US20030004126A1

  公开（公告）日：2003-01-02

  The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and an opioid or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

  本发明提供了一种治疗与疼痛有关的病症并减轻相关症状的方法，包括向哺乳动物（包括人）施用腺苷A1激动剂或其生理上可接受的盐或溶剂以及阿片类药物或其生理上可接受的盐或溶剂。本发明还提供了包含上述组合物的制药配方和患者包。
• Formulatios of adenosine a1 agonists
  申请人：——

  公开号：US20030004128A1

  公开（公告）日：2003-01-02

  The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and an NSAID, e.g. a COX-2 inhibitor, or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

  本发明提供了一种治疗与疼痛相关的疾病并缓解相关症状的方法，包括向哺乳动物（包括人类）投与腺苷A1激动剂或其生理上可接受的盐或溶剂以及NSAID，例如COX-2抑制剂或其生理上可接受的盐或溶剂。本发明还提供了包含上述组合物的制药配方和患者包装。
• FORMULATIONS OF ADENOSINE A1 AGONISTS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1239879A2

  公开（公告）日：2002-09-18
• FORMULATIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1239879B1

  公开（公告）日：2004-02-25